Korea Investment & Securities, KB Investments & Securities and NH Investments & Securities are also winners, along with Citi and Credit Suisse in the foreign categories.
Third largest IPO in Korean history prices at the top of the range, but is still expected to make a solid secondary market debut after amassing strong demand.
Investors piled into the biologic drug manufacturer’s listing despite a young corporate history and an unimpressive track record of generating profits.
South Korea’s biggest conglomerate sets out with ambitious plans to raise as much as $2 billion from the listing of its contract drug unit on the Korean stock market.